Place of therapeutic cannabis in France and safety data: A literature review

Corso, Baptiste; Bacle, Astrid; Demay, E.; Mercerolle, Marion; Pelletier, Romain; Gicquel, Thomas; Daré, Brendan Le

doi:10.1016/j.pharma.2023.02.002

Cited by 2 publications

(3 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, 95–99% of plasma THC is bound to plasma proteins. Hence, competitive protein binding with other drugs may also change the PK of THC [ 104 , 105 ]. Additionally, there is controversy over whether CBD can be converted to THC in the body [ 106 ].…”

Section: Cbd/thc Pk-based Drug Interactionsmentioning

confidence: 99%

“…The increase in plasma volume may result in lower plasma CBD/THC concentrations, while the reduction in plasma protein levels may exacerbate the concentration decrease. In contrast, the free cannabinoid concentrations may increase due to the decreased plasma protein level, as CBD and THC have high protein binding (95–99% for THC) [ 104 , 105 ]. For elimination, Grant et al suggested that the clearance of THC during pregnancy can increase up to 2-fold, and the THC exposure may be decreased [ 141 ].…”

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

“…Due to brain diseases in older adults, the permeability of the blood–brain barrier may increase, therefore increasing the distribution of CBD/THC in the brain [ 207 ]. Plasma protein, mainly lipoproteins, followed by albumin, is bound to 95–99% of plasma THC [ 104 , 105 ]. The change in lipoproteins and albumin may impact the concentration of CBD/THC.…”

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

See 2 more Smart Citations

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Qian,

Beers,

Jackson

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug–drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined. This review summarizes the published studies on CBD and THC–drug interactions, outlines the mechanisms involved, discusses the physiological considerations in pharmacokinetics (PK) and DDI studies in special populations (including pregnant and lactating women, pediatrics, older adults, patients with hepatic or renal impairments, and others), and presents modeling approaches that can describe the DDIs associated with CBD and THC in special populations. The PK of CBD and THC in special populations remain poorly characterized, with limited studies investigating DDIs involving CBD/THC in these populations. Therefore, it is critical to evaluate potential DDIs between CBD/THC and medications that are commonly used in special populations. Modeling approaches can aid in understanding these interactions.

show abstract

Section: Cbd/thc Pk-based Drug Interactionsmentioning

confidence: 99%

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

Section: Cbd/thc Studies In Special Populationsmentioning

confidence: 99%

See 1 more Smart Citation

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Qian,

Beers,

Jackson

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts

Mick,

Douek

2024

Pain Ther

View full text Add to dashboard Cite

Interest in medical cannabis and cannabisbased medicinal products (CBMPs) has increased greatly in recent years. Two cannabinoids are of principal importance; delta-9-tetrahydrocannabinol (∆9-THC), the primary psychoactive component, and also cannabidiol (CBD), considered non-intoxicating. Each has distinct mechanisms of action and different therapeutic potentials.CBMPs differ in their ∆9-THC and CBD components; predominantly ∆9-THC, balanced formulations with equivalent ∆9-THC and CBD elements, and CBD-predominant products. In this narrative review, we evaluate the published evidence for the clinical benefits of CBMPs and overall benefits in well-being. We also review the overall safety profile and discuss the potential for dependence with CBMPs. Evidence can be drawn from a wide range of randomized and other controlled studies and from observational real-world studies. Most data from observational registry studies are supportive of ∆9-THC-based products (∆9-THC-predominant or balanced CBMPs) in the management of chronic neuropathic pain. Balanced products are also effective in reducing spasticity in multiple sclerosis. Most CBMPs show benefit in providing symptomatic benefits in reducing anxiety, nausea, and in improving sleep, but the place of specific products is more subtle, and choice guided by specific circumstances. Symptomatic improvements are accompanied by improved quality of life and well-being. Safety data indicate that CBMPs are generally well tolerated in most patients without specific contraindications. The majority of adverse effects are non-serious, and transient; most are principally associated with ∆9-THC and are dose-dependent. In contrast to recreational cannabis use, there is little evidence from clinical studies that CBMPs have any potential for dependence.

show abstract

Place of therapeutic cannabis in France and safety data: A literature review

Cited by 2 publications

References 62 publications

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

CBD and THC in Special Populations: Pharmacokinetics and Drug–Drug Interactions

Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts

Contact Info

Product

Resources

About